Skull Base Chordoma and Chondrosarcoma: Influence of Clinical and Demographic Factors on Prognosis: A SEER Analysis

Bohman, Leif‐Erik; Koch, Matthew J.; Bailey, Robert L.; Alonso‐Basanta, Michelle; Lee, John Y.K.

doi:10.1016/j.wneu.2014.07.005

Cited by 112 publications

(80 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study also identified that chordomas were more common among Caucasians in both populations, while a higher percentage of pediatric chordoma patients were African American, Hispanic, and Asian/Pacific Islander, compared to adults. These findings are consistent with previous small retrospective studies in which over 80% of chordoma patients were Caucasians [1,6,7,10,11]. …”

Section: Discussionsupporting

confidence: 93%

“…Similar to previously published data, this study identified a higher incidence of chordomas among males in both the pediatric and adult populations [1,7,10,11]. This study also identified that chordomas were more common among Caucasians in both populations, while a higher percentage of pediatric chordoma patients were African American, Hispanic, and Asian/Pacific Islander, compared to adults.…”

Section: Discussionsupporting

confidence: 90%

“…Previous studies have also shown that younger age is associated with the best prognosis, and that increasing age was associated with both higher recurrence and mortality [6,7,11]. Chambers et al [6] reported on 594 patients with cranial chordomas and reported that patients 60-69 years of age have a 2.20 times greater rate of mortality, and patients aged 70 and older had a 4.70 times greater rate of mortality, compared to patients 40-49 years.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Pediatric Chordomas: A Population-Based Clinical Outcome Study Involving 86 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1973-2011)

et al. 2016

View full text Add to dashboard Cite

Background/Aims: Primary chordomas, rare cancers arising from the notochord remnants, are extremely rare in the pediatric population. This study examined a large cohort of primary chordoma patients to determine factors impacting prognosis and survival. Methods: Demographic and clinical data on 1,358 primary chordoma patients (86 pediatric patients ≤19 years of age and 1,272 adult patients ≥20 years of age) were abstracted from the Surveillance, Epidemiology, and End Result (SEER) database (1973-2011). Results: Pediatric primary chordomas present most often as small tumors <4 cm in the cranium of male Caucasians. Despite the majority of primary chordomas presenting with locoregional involvement (90.4%), pediatric patients had more distant disease (14.8 vs. 9.2%, p < 0.05). Survival among pediatric patients having surgery only was significantly longer than for adults (22.5 vs. 14.3 years, p < 0.001). Overall survival was longer (17.2 vs. 12.6 years) and overall mortality was lower in pediatric patients (38.4 vs. 49.8%), but cancer-specific mortality was higher (37.2 vs. 28.6%, p < 0.005). Conclusions: Pediatric primary chordomas present most often as small tumors <4 cm in the cranium of male Caucasians. Despite having a higher rate of metastasis, they have prolonged survival compared to adults. Surgical resection significantly improves survival in pediatric primary chordoma patients, and should be considered as first-line therapy in all eligible children.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pediatric Chordomas: A Population-Based Clinical Outcome Study Involving 86 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1973-2011)

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Distinction of these 2 tumors is important, because SBCSs of the skull base are reported to show significantly better prognosis than chordomas. 1,4 Clinicians and pathologists are occasionally confronted by diagnostic problems caused by radiological and histological overlap between SBCSs and chordomas, especially with the "chondroid" subtype of chordomas. Recently, brachyury, a new immunohistochemical marker for chordoma, has been used to help distinguish chordomas from chondrosarcomas in addition to traditional markers, including cytokeratin and epithelial membrane antigen (EMA).…”

mentioning

confidence: 99%

Genetic characterization of skull base chondrosarcomas

Kanamori¹,

Kitamura²,

Kimura

et al. 2015

JNS

View full text Add to dashboard Cite

A lthough chondrosarcoma is the third most frequent primary malignancy of bone after myeloma and osteosarcoma, 7 skull base chondrosarcomas (SBCSs) are rare, accounting for only approximately 1% of all chondrosarcomas. 6 In France, intracranial chondrosarcomas account for 0.05% of all brain tumors, 21 and together with chordoma, they account for 0.09% of central nervous system tumors in the United States.5 However, among malignant bone tumors in the skull base, SBCS and chordoma are the 2 major histological types. Distinction of these 2 tumors is important, because SBCSs of the skull base are reported to show significantly better prognosis than chordomas. 1,4 Clinicians and pathologists are occasionally confronted by diagnostic problems caused by radiological and histological overlap between SBCSs and chordomas, especially with the "chondroid" subtype of chordomas. Recently, brachyury, a new immunohistochemical marker for chordoma, has been used to help distinguish chordomas from chondrosarcomas in addition to traditional markers, including cytokeratin and epithelial membrane antigen (EMA). 18Little is known about the genetic characteristics of SBCSs, because unlike for chordomas and extracranial chondrosarcomas, there have been no reports of whole-genome analysis of a case series of SBCSs to date. An early cytogenetic study of a single case of SBCS was described, obJect Although chondrosarcomas rarely arise in the skull base, chondrosarcomas and chordomas are the 2 major malignant bone neoplasms occurring at this location. The distinction of these 2 tumors is important, but this distinction is occasionally problematic because of radiological and histological overlap. Unlike chordoma and extracranial chondrosarcoma, no case series presenting a whole-genome analysis of skull base chondrosarcomas (SBCSs) has been reported. The goal of this study is to clarify the genetic characteristics of SBCSs and contrast them with those of chordomas. methods The authors analyzed 7 SBCS specimens for chromosomal copy number alterations (CNAs) using comparative genomic hybridization (CGH). They also examined IDH1 and IDH2 mutations and brachyury expression. results In CGH analyses, the authors detected CNAs in 6 of the 7 cases, including chromosomal gains of 8q21.1, 19, 2q22-q32, 5qcen-q14, 8q21-q22, and 15qcen-q14. Mutation of IDH1 was found with a high frequency (5 of 7 cases, 71.4%), of which R132S was most frequently mutated. No IDH2 mutations were found, and immunohistochemical staining for brachyury was negative in all cases. coNclusioNs To the best of the authors' knowledge, this is the first whole-genome study of an SBSC case series. Their findings suggest that these tumors are molecularly consistent with a subset of conventional central chondrosarcomas and different from skull base chordomas.

show abstract

“…In dogs, more than 60% of chondrosarcomas have been identified in flat bones like ribs and pelvis (Popovitch, Weinstein, Goldsmidt, & Shofer, 1994;Bohman, Koch, Bailey, Basanta, & Lee, 2014). It usually presents slow clinical evolution with a late metastatic process.…”

Section: Chondrosarcomamentioning

confidence: 99%

Repair of Defect in Thoracic Wall Associated with Neoplasms—Literature Review

Pazzini¹,

Huppes²,

Castro³

et al. 2018

JAS

View full text Add to dashboard Cite

The major malignant tumors found on the chest wall are sarcomas, including osteosarcomas, chondrosarcomas, fibrosarcomas, and hemangiosarcomas. Treatment of cancer, as well as chronic chest wall conditions, require radical surgical excision of the involved tissues. In addition to surgery, chemotherapy plays a role as adjuvant treatment in tumors affecting the chest wall, reducing chances of metastasis and prolonging the disease. The restoration of the chest wall has the main objective to restore the respiratory function, for this, a procedure is necessary that keeps the chest closed and stable. There are many materials used for chest repair, such as autogenous, synthetic, homologous and heterologous tissues. The main objective of this literature review is to address the main malignancies that affect the chest wall, as well as the resources most used to repair the damage caused by aggressive surgery in an attempt to promote greater safety margins.

show abstract

Skull Base Chordoma and Chondrosarcoma: Influence of Clinical and Demographic Factors on Prognosis: A SEER Analysis

Cited by 112 publications

References 27 publications

Pediatric Chordomas: A Population-Based Clinical Outcome Study Involving 86 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1973-2011)

Pediatric Chordomas: A Population-Based Clinical Outcome Study Involving 86 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1973-2011)

Genetic characterization of skull base chondrosarcomas

Repair of Defect in Thoracic Wall Associated with Neoplasms—Literature Review

Contact Info

Product

Resources

About